A Double-blind, Placebo-controlled, Randomized, Multicenter Phase III Study Evaluating the Efficacy and Safety of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-positive Metastatic Gastroesophageal Junction and Gastric Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Pertuzumab (Primary) ; Capecitabine; Cisplatin; Fluorouracil; Trastuzumab
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms JACOB
- Sponsors Roche
- 29 Oct 2019 Planned End Date changed from 1 Oct 2019 to 1 Dec 2019.
- 02 Jul 2019 Planned End Date changed from 29 Jun 2019 to 1 Oct 2019.
- 02 Apr 2019 Planned End Date changed from 15 Dec 2021 to 29 Jun 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History